Shots: In the P-I study, the companies will evaluate the OBDS with Ionis’ drug for in vitro compatibility and performance as well as in vivo safety, tolerability, and performance in a preclinical canine model Progenity expects that the alliance could demonstrate the versatility of OBDS in delivering a range of different molecules Ionis’ novel antisense […]Read More
